BOSSI, ELISA
 Distribuzione geografica
Continente #
NA - Nord America 459
EU - Europa 286
AS - Asia 169
SA - Sud America 20
Continente sconosciuto - Info sul continente non disponibili 3
Totale 937
Nazione #
US - Stati Uniti d'America 455
IT - Italia 98
SG - Singapore 82
RU - Federazione Russa 50
DE - Germania 46
IE - Irlanda 42
CN - Cina 25
HK - Hong Kong 25
SE - Svezia 18
ID - Indonesia 17
BR - Brasile 16
TR - Turchia 8
IN - India 7
GB - Regno Unito 6
AT - Austria 5
CA - Canada 4
FI - Finlandia 4
UA - Ucraina 4
EU - Europa 3
FR - Francia 3
LT - Lituania 3
AR - Argentina 2
CH - Svizzera 2
DK - Danimarca 2
NL - Olanda 2
PH - Filippine 2
AZ - Azerbaigian 1
CO - Colombia 1
PE - Perù 1
PT - Portogallo 1
UZ - Uzbekistan 1
VN - Vietnam 1
Totale 937
Città #
Ann Arbor 211
Singapore 51
Dublin 42
Milan 32
Frankfurt am Main 28
Wilmington 27
Hong Kong 25
Chandler 23
New York 22
Santa Clara 20
Jakarta 17
Fairfield 12
Ashburn 11
Shanghai 11
Seattle 9
Cambridge 8
Woodbridge 8
Houston 7
Princeton 6
Fremont 5
Kocaeli 5
Los Angeles 5
Duncan 4
Helsinki 4
Nuremberg 4
Rome 4
Turin 4
Ankara 3
Bologna 3
Colorado Springs 3
Lawrence 3
Romola 3
Abbiategrasso 2
Aurora 2
Beijing 2
Bonndorf 2
Brugherio 2
Carugate 2
Düsseldorf 2
Fisciano 2
Guangzhou 2
Hebei 2
Lissone 2
Manila 2
Monmouth Junction 2
Monza 2
Moscow 2
Nanjing 2
Novo Hamburgo 2
Ottawa 2
São Paulo 2
Toronto 2
Vicenza 2
Vienna 2
Altamura 1
Andover 1
Austin 1
Baku 1
Bari 1
Boardman 1
Bogotá 1
Brasília 1
Canobbio 1
Carate Brianza 1
Chicago 1
Corsico 1
Desio 1
Falls Church 1
Grafing 1
Guarulhos 1
Guernica 1
Ho Chi Minh City 1
Hounslow 1
Hyderabad 1
Ivrea 1
Jacksonville 1
Jinan 1
Kaunas 1
Lauterbourg 1
Leawood 1
Leopoldina 1
London 1
Mogi das Cruzes 1
Moreno 1
Morretes 1
Mountain View 1
Munich 1
Nanchang 1
Navoiy 1
Newark 1
Niterói 1
Paracatu 1
Portsmouth 1
Poços de Caldas 1
Pune 1
Redmond 1
Rocca Canavese 1
Salvador 1
San Diego 1
Santo Afonso 1
Totale 710
Nome #
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 275
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 205
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 160
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 84
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706) 81
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 72
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 67
Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies 34
Totale 978
Categoria #
all - tutte 4.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.070


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202036 0 0 0 0 0 0 0 0 0 21 9 6
2020/2021263 9 2 22 35 26 37 28 25 19 18 25 17
2021/202262 14 14 11 3 1 5 2 2 1 1 3 5
2022/2023101 6 27 10 3 11 12 4 2 5 1 10 10
2023/2024186 5 8 20 9 30 45 30 2 19 2 2 14
2024/2025289 10 33 25 21 33 29 38 9 42 49 0 0
Totale 978